Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583435 | 0.90 | MET (0.62) | METRPS6KA3DRD5HTR2CHTR6 | |
| SCHEMBL12808127 | 0.88 | MET (0.51) | METRPS6KA3DRD5HTR2CHTR6 | |
| SCHEMBL1583727 | 0.87 | MET (0.71) | METRPS6KA3KDM4EALDH1A1MAPT | |
| SCHEMBL12807922 | 0.84 | MET (0.56) | METRPS6KA3KDM4EALDH1A1MAPT | |
| SCHEMBL1583574 | 0.84 | MET (0.56) | METRPS6KA3DRD5HTR2CHTR6 | |
| SCHEMBL1583372 | 0.83 | MET (0.57) | METRPS6KA3KDM4EALDH1A1MAPT | |
| SCHEMBL1983683 | 0.82 | MET (0.61) | METRPS6KA3KDM4EALDH1A1MAPT | |
| SCHEMBL1993082 | 0.81 | MET (0.62) | METRPS6KA3ALDH1A1DRD5HTR2C | |
| SCHEMBL12595668 | 0.81 | MET (0.56) | METRPS6KA3ALDH1A1HSD17B10DRD5 | |
| SCHEMBL1077503 | 0.80 | MET (0.51) | METRPS6KA3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2011042367-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AG (DE) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270905-A1 | FLUORINATED 2,6-DIALKYL-3,5-DICYANO-4-(1H-INDAZOL-5-YL)-1,4-DIHYDROPYRIDINES AND METHODS OF USE THEREOF | MET, DCK, RET | MET 1/4885RPS6KA3 434/4885KDM4E 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.